Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Radiotherapy & Radiosurgery
Brachytherapy for prostate cancer
What brachytherapy for prostate cancer is, how low-dose rate (LDR) seed implants and high-dose rate (HDR) temporary radiation destroy tumour cells from inside the prostate, clinical evidence on disease control and urinary function, approximate costs in Turkey compared with the UK, US and Germany, what recovery feels like, potential complications and questions to ask your multidisciplinary team.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Radiotherapy & Radiosurgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Brachytherapy for Prostate Cancer
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is brachytherapy for prostate cancer and how does internal radiation work?
Brachytherapy for prostate cancer is an internal radiotherapy that places sealed radioactive sources directly inside the prostate gland. Unlike external beam radiotherapy, where ionizing rays pass through the skin, bladder and rectum, brachytherapy positions radiation directly into the tumour tissue. Because radiation dose falls off rapidly beyond the prostate capsule, oncologists deliver a concentrated therapeutic dose to malignant cells while sparing adjacent healthy organs. Hospitals in Turkey offer this technique as a definitive curative option for organ-confined disease, integrated within specialised oncology treatments in Turkey.
Internal radiation is delivered via two methods: low-dose rate (LDR) seed implants that remain permanently, or high-dose rate (HDR) temporary catheters that deliver radiation over several minutes before removal. This guide explains how the treatment works, clinical evidence, costs compared with the UK, US and Germany, recovery milestones and clinic selection.
Does brachytherapy for prostate cancer work? Evidence and long-term control
Clinical evidence and guidelines from the European Association of Urology (EAU), American Society for Radiation Oncology (ASTRO) and NICE confirm that brachytherapy is highly effective for localised prostate cancer. For low-risk and favourable intermediate-risk disease, 10-to-15-year biochemical recurrence-free survival rates range from 85% to 95%, matching results from robotic radical prostatectomy and modern external beam radiotherapy.
The main advantage is dose escalation: placing radioactive sources inside the gland allows a higher local dose than external radiation can safely provide alone. For higher-risk localised tumours, brachytherapy is often combined with external beam radiotherapy as a boost. However, brachytherapy cannot treat cancer that has spread beyond the pelvis, and it does not guarantee recurrence-free survival if microscopic cells exist outside the treatment margins.
Low-dose rate (LDR) seed implants versus high-dose rate (HDR) temporary brachytherapy
Understanding the distinction between LDR and HDR brachytherapy helps you evaluate clinical recommendations:
In LDR brachytherapy, 60 to 120 rice-sized titanium seeds containing Iodine-125 or Palladium-103 are permanently placed in the prostate through thin needles. They emit continuous low-dose radiation over several months until the isotope decays completely; the inert titanium shells remain safely inside the gland for life.
In HDR brachytherapy, temporary hollow needles or catheters are inserted into the gland. A computer-controlled afterloader drives an Iridium-192 source through each catheter, pausing at precise dwell positions for calculated minutes to deliver the entire dose. The source is then retracted into a shielded safe and all catheters are removed. No radioactive material remains in your body. HDR is used either alone in fractional sessions or as a boost alongside external beam radiation.
Brachytherapy for prostate cancer cost in Turkey compared with the UK, US and Germany
The figures below represent approximate cost ranges for brachytherapy across different countries. They reflect private healthcare pricing rather than hospital-specific quotes, and depend on whether LDR seeds or HDR delivery is used, pre-treatment imaging requirements and hospital observation.
| Country | Approximate cost range |
|---|---|
| Turkey | €4,500 – €9,500 |
| United Kingdom | €9,000 – €18,000 |
| United States | €14,000 – €35,000 |
| Germany | €8,500 – €16,000 |
Several clinical factors influence the brachytherapy for prostate cancer price. In LDR brachytherapy, custom ordering of radioactive seeds calibrated to your prostate volume represents a fixed material expense. For HDR, treatment planning software and linear facility usage drive the pricing. What changes the brachytherapy for prostate cancer cost: LDR seed procurement, HDR treatment planning, anaesthesia type, and whether overnight hospital observation is needed. A comprehensive package in Turkey usually includes pre-implant transrectal ultrasound or MRI simulation, the procedure and consumable seeds or catheters, medical physicist planning, 24-hour post-implant CT dosimetry, overnight stay, medication and airport transfers.
Brachytherapy compared with radical prostatectomy and external beam radiotherapy
Localised prostate cancer offers several evidence-based treatment options. The right choice depends on tumour risk category, prostate volume, baseline urinary symptoms and personal priorities.
| Treatment option | Best suited to | Key clinical differences and limits |
|---|---|---|
| LDR Seed Brachytherapy | Low-risk and favourable intermediate-risk localised disease | Single short procedure; minimal stress incontinence risk; temporary urinary irritation for 6–12 months |
| HDR Brachytherapy (Boost or Solo) | Intermediate-to-high risk (boost) or select localised tumours | No permanent radioactivity left inside; computer-controlled dwell times; requires temporary catheter insertion |
| External Beam Radiotherapy (EBRT / Tomotherapy) | All risk groups, including suspected nodal involvement | Non-invasive daily fractions over 4–7 weeks; radiation travels through healthy tissue to reach the prostate |
| Robotic Radical Prostatectomy | Localised cancer in surgical candidates wanting gland removal | Complete tissue histology; higher initial risk of stress incontinence and erectile dysfunction; surgical downtime |
Compared to surgery, brachytherapy carries a much lower rate of long-term stress urinary incontinence (under 2–3% versus 10–20% after surgery). Compared to external beam options such as tomotherapy, which deliver daily radiation fractions over several weeks, brachytherapy completes radiation in one or two sessions with steeper dose drop-off. Intracranial techniques like gamma knife show how concentrated radiation works in cranial care; prostate brachytherapy applies similar focal precision directly within pelvic anatomy.
Who is an appropriate candidate for prostate seed therapy, and who is not?
International guidelines (EAU, ASTRO) define strict clinical criteria for prostate brachytherapy. Favourable candidates typically have clinical stage T1c–T2a disease, a Gleason score of 6 or favourable 3+4=7, initial PSA under 10 ng/mL, and a prostate volume between 20 and 50–60 cc so the pubic bone does not block needle access. A low International Prostate Symptom Score (IPSS < 12) with good urinary flow is also essential.
You are less suited to brachytherapy if your prostate gland exceeds 60 cc (unless reduced beforehand with hormone therapy), if you have severe baseline urinary obstruction, or if you have had a prior transurethral resection of the prostate (TURP) that left a large cavity where seeds cannot seat securely. Significant extraprostatic extension or suspected nodal spread also requires wider external radiation or systemic therapy rather than seed monotherapy.
The treatment procedure step by step: planning, needle placement and radiation delivery
Prostate brachytherapy is performed in four coordinated steps by a multidisciplinary team:
First, pre-implant simulation uses transrectal ultrasound or MRI to capture precise cross-sectional images of your prostate. A medical physicist uses computerized dosimetry software to calculate the exact needle trajectories and radiation dose map to cover the tumour while protecting the urethra and rectum.
Second, on the procedure day, you receive general or spinal anaesthesia and are positioned comfortably in lithotomy. A temporary urinary catheter is inserted to visualise the urethra under live imaging.
Third, an ultrasound probe is positioned in the rectum, and a calibrated template grid is placed against the perineum. Fine needles are inserted through the perineal template into the prostate under live ultrasound. For LDR, radioactive seeds are released as needles retract. For HDR, hollow catheters connect to an automated afterloader that drives an Iridium-192 source into each channel for planned minutes before full removal.
Fourth, recovery includes ice packs to the perineum, observation, catheter removal once urine flows freely, and a CT scan within 24 hours to verify dose coverage.
Travel schedule and brachytherapy for prostate cancer recovery milestones
Patients travelling for brachytherapy for prostate cancer Turkey typically spend five to seven nights abroad. A standard schedule involves arrival and pre-operative bloods on Day 1, imaging simulation on Day 2, the implantation procedure on Day 3, overnight monitoring and catheter removal on Day 4, post-implant CT dosimetry verification on Day 5, and final doctor consultation on Day 6 before flying home on Day 7.
Physical brachytherapy for prostate cancer recovery proceeds in predictable stages:
- Days 1 to 3: Mild perineal bruising, tenderness and faint blood in the urine or semen. Most patients walk comfortably within hours after anaesthesia wears off.
- Weeks 1 to 4: Acute radiation swelling triggers urinary frequency, urgency and a weaker stream. Alpha-blockers (such as tamsulosin) and mild pain relievers help relax the bladder neck.
- Months 2 to 6: Urinary irritation peaks around weeks four to eight and then gradually subsides as LDR radiation decays or HDR tissue inflammation calms.
- Months 6 to 12: Over 90% of men return to baseline urinary function. Desk work resumes in about one week; avoid heavy lifting and cycling for four to six weeks.
PSA monitoring and life after treatment: what realistic outcomes look like
Because radiation destroys cancer cells gradually rather than excising the prostate, your PSA level does not drop to zero overnight. It declines steadily over 18 to 36 months toward its lowest level (the PSA nadir), usually below 0.5 ng/mL, which indicates durable disease control. PSA checks are performed every three to six months for two years, then annually.
Between 12 and 30 months after brachytherapy, 20% to 40% of patients experience a "PSA bounce"—a temporary rise in PSA followed by a spontaneous drop without cancer recurrence. Experienced teams monitor this without rushing to invasive re-biopsies or hormone therapy unless levels meet the formal Phoenix failure criteria (nadir plus 2.0 ng/mL).
For LDR patients, simple radiation safety rules apply for the first two months: avoid holding infants or pregnant women on your lap for long periods, and use condoms during intimacy for a few weeks in case of rare seed passage. Erectile function preservation rates remain higher than with surgery during the first two years, though gradual decline can occur over three to five years.
Potential side effects, urinary complications and radiation risks
While brachytherapy is highly focused, radiation and needle punctures affect adjacent pelvic tissues. Evidence from ASTRO and EAU highlights the main risks:
Acute urinary symptoms—frequency, urgency, nocturia and mild burning—occur in 80% to 90% of men during the first three months. Acute urinary retention, where swelling temporarily blocks urination, affects 5% to 10% of patients and is managed with temporary catheterisation and alpha-blockers.
Bowel side effects are rare; mild radiation proctitis (rectal urgency or minor bleeding) occurs in under 3% to 5% of cases and usually resolves spontaneously. Urethral stricture (scarring) develops in 1% to 4% of men years later and responds to minor dilation. Seed migration in LDR is uncommon, with stray seeds posing no clinical harm. Secondary radiation-induced cancers occur in fewer than 1% of patients over 10 to 15 years.
How to choose an oncology centre in Turkey and essential questions to ask
Selecting an oncology centre in Turkey requires verifying clinical qualifications, dosimetry technology and multidisciplinary care. Brachytherapy demands close teamwork between an experienced radiation oncologist, a medical physicist and a urologist. Check that the hospital holds national licensing and reviews cases in a multidisciplinary tumour board. Learn how it works when arranging medical travel, and request a written clinical assessment and free quote before committing.
Red flags include clinics that quote a price without reviewing your biopsy pathology and MRI, promises of zero urinary side effects or guaranteed sexual potency, absence of a dedicated medical physicist, or pressure to pay before receiving a detailed treatment plan.
Questions to ask your clinical team:
- How many prostate brachytherapy procedures does your team perform each year?
- Do you recommend LDR seed implantation or HDR brachytherapy for my Gleason score and prostate volume?
- Will a medical physicist perform computerized dosimetric planning and post-implant CT verification?
- What is your emergency protocol if I experience acute urinary retention after returning home?
- Are all consumable seeds, needles, anaesthesia and hospital stays included in my written quotation?
Hospitals with Oncology in Turkey
Frequently asked questions
Brachytherapy for prostate cancer is an internal radiotherapy procedure where radioactive sources are placed directly inside the prostate gland. It treats localised prostate cancer with high radiation doses concentrated on the tumour while minimising radiation exposure to the nearby bladder, rectum and healthy pelvic tissues.
Yes, extensive clinical research from international oncology societies confirms that for localised, low-risk and favourable intermediate-risk prostate cancer, brachytherapy achieves 10-to-15-year cancer-control rates equivalent to surgical removal (radical prostatectomy) and external beam radiation, with high rates of urinary continence preservation.
Low-dose rate (LDR) brachytherapy implants tiny permanent radioactive seeds (such as Iodine-125) that slowly release radiation over several months. High-dose rate (HDR) brachytherapy temporarily inserts hollow catheters to deliver high-intensity radiation over several minutes using an automated afterloader, leaving no radioactive material in your body afterwards.
Brachytherapy for prostate cancer cost in Turkey typically ranges from €4,500 to €9,500, compared with €9,000 to €18,000 in the UK and up to €35,000 in the US. The price covers pre-treatment simulation, radioactive seeds or HDR delivery, hospital stay, anaesthesia and medical follow-up.
Most patients walk comfortably the day after the procedure and resume light daily activities within two to five days. Perineal soreness and minor bruising resolve within one to two weeks, while mild urinary frequency and urgency can persist for several months before gradually subsiding to baseline levels.
The implantation procedure is performed under spinal or general anaesthesia, ensuring you feel no pain during treatment. Afterwards, most men experience mild perineal discomfort, swelling and an ache that resembles sitting on a small ball, which is easily managed with mild oral painkillers for a few days.
Brachytherapy avoids major surgical incisions, offers significantly lower rates of long-term stress urinary incontinence, and allows faster return to work. However, brachytherapy causes temporary urinary irritation from radiation, whereas surgery removes the prostate completely but carries higher initial risks of erectile dysfunction and leakage.
The radiation from permanent LDR seeds is absorbed almost entirely within the prostate tissue. Very faint radiation can escape the skin during the first two months, so doctors advise avoiding holding infants or pregnant women on your lap for extended periods. HDR brachytherapy leaves no radioactivity whatsoever.
Erectile function preservation rates remain higher in the first two years after brachytherapy than after radical prostatectomy. Over three to five years, however, gradual radiation-induced vascular changes may lead to erectile difficulties in 20% to 40% of men, which often respond well to oral medications.
Patients travelling for brachytherapy for prostate cancer Turkey typically spend five to seven nights in the country. This schedule allows for pre-treatment MRI simulation, the implantation procedure, overnight hospital monitoring, post-implant dosimetric verification imaging, catheter removal and a final consultation before clearing you for your return flight.
Patient stories